DOCSLIB.ORG

Strategies for Clinical Implementation and Quality Management of PET Tracers Strategies For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Strategies for Clinical Implementation and Quality Management of PET Tracers Strategies For Strategies for Clinical Implementation and Quality Management of PET Tracers Strategies for Positron emission tomography has made a major impact on patient Clinical Implementation The IAEA Safety Glossary clarifies and harmonizes terminology diagnosis, disease staging, disease management and therapy follow-up, and usagebut its in complexities the IAEA safety create standards. a need for more To this robust end, quality it defines management and explainsprogrammes. scientific This and book technical focuses on terms the clinical used settingin the and IAEA aims safety to raise and Quality Management standardsawareness and inof otherthe issues safety involved, related as publications,well as suggesting and ways provides to reduce informationrisk. A proactive on their usage.approach The is Safety encouraged Glossary to each provides aspect guidance of parametric of PET Tracers primarilyrelease, for andthe practicaldrafters, test reviewers methods areand proposed. users of This IAEA book safety will be of standards.interest However, to both researchers it is also a and source practitioners of information in busy forclinical drafters settings. and users of other safety and security related IAEA publications and for other IAEA staff, and is of wider interest in Member States. INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA @ ISBN 978–92–0–107008–1 09-01471_P1344_covI-IV.indd 1 2009-03-17 10:11:58 STRATEGIES FOR CLINICAL IMPLEMENTATION AND QUALITY MANAGEMENT OF PET TRACERS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GUATEMALA OMAN ALBANIA HAITI PAKISTAN ALGERIA HOLY SEE PALAU ANGOLA HONDURAS PANAMA ARGENTINA HUNGARY PARAGUAY ARMENIA ICELAND PERU AUSTRALIA INDIA PHILIPPINES AUSTRIA INDONESIA POLAND AZERBAIJAN IRAN, ISLAMIC REPUBLIC OF PORTUGAL BANGLADESH IRAQ QATAR BELARUS IRELAND REPUBLIC OF MOLDOVA BELGIUM ISRAEL ROMANIA BELIZE ITALY RUSSIAN FEDERATION BENIN JAMAICA SAUDI ARABIA BOLIVIA JAPAN SENEGAL BOSNIA AND HERZEGOVINA JORDAN SERBIA BOTSWANA KAZAKHSTAN SEYCHELLES BRAZIL KENYA SIERRA LEONE BULGARIA KOREA, REPUBLIC OF SINGAPORE BURKINA FASO KUWAIT SLOVAKIA CAMEROON KYRGYZSTAN SLOVENIA CANADA LATVIA SOUTH AFRICA CENTRAL AFRICAN LEBANON SPAIN REPUBLIC LIBERIA SRI LANKA CHAD LIBYAN ARAB JAMAHIRIYA SUDAN CHILE LIECHTENSTEIN SWEDEN CHINA LITHUANIA SWITZERLAND COLOMBIA LUXEMBOURG SYRIAN ARAB REPUBLIC COSTA RICA MADAGASCAR CÔTE D’IVOIRE MALAWI TAJIKISTAN CROATIA MALAYSIA THAILAND CUBA MALI THE FORMER YUGOSLAV CYPRUS MALTA REPUBLIC OF MACEDONIA CZECH REPUBLIC MARSHALL ISLANDS TUNISIA DEMOCRATIC REPUBLIC MAURITANIA TURKEY OF THE CONGO MAURITIUS UGANDA DENMARK MEXICO UKRAINE DOMINICAN REPUBLIC MONACO UNITED ARAB EMIRATES ECUADOR MONGOLIA UNITED KINGDOM OF EGYPT MONTENEGRO GREAT BRITAIN AND EL SALVADOR MOROCCO NORTHERN IRELAND ERITREA MOZAMBIQUE UNITED REPUBLIC ESTONIA MYANMAR OF TANZANIA ETHIOPIA NAMIBIA UNITED STATES OF AMERICA FINLAND NEPAL URUGUAY FRANCE NETHERLANDS UZBEKISTAN GABON NEW ZEALAND VENEZUELA GEORGIA NICARAGUA VIETNAM GERMANY NIGER YEMEN GHANA NIGERIA ZAMBIA GREECE NORWAY ZIMBABWE The Agency’s Statute was approved on 23 October 1956 by the Conference on the Statute of the IAEA held at United Nations Headquarters, New York; it entered into force on 29 July 1957. The Headquarters of the Agency are situated in Vienna. Its principal objective is “to accelerate and enlarge the contribution of atomic energy to peace, health and prosperity throughout the world’’. STRATEGIES FOR CLINICAL IMPLEMENTATION AND QUALITY MANAGEMENT OF PET TRACERS INTERNATIONAL ATOMIC ENERGY AGENCY VIENNA, 2009 COPYRIGHT NOTICE All IAEA scientific and technical publications are protected by the terms of the Universal Copyright Convention as adopted in 1952 (Berne) and as revised in 1972 (Paris). The copyright has since been extended by the World Intellectual Property Organization (Geneva) to include electronic and virtual intellectual property. Permission to use whole or parts of texts contained in IAEA publications in printed or electronic form must be obtained and is usually subject to royalty agreements. Proposals for non-commercial reproductions and translations are welcomed and considered on a case-by-case basis. Enquiries should be addressed to the IAEA Publishing Section at: Sales and Promotion, Publishing Section International Atomic Energy Agency Wagramer Strasse 5 P.O. Box 100 1400 Vienna, Austria fax: +43 1 2600 29302 tel.: +43 1 2600 22417 email: [email protected] http://www.iaea.org/books © IAEA, 2009 Printed by the IAEA in Austria March 2009 STI/PUB/1344 IAEA Library Cataloguing in Publication Data Strategies for clinical implementation and quality management of PET tracers. — Vienna : International Atomic Energy Agency, 2009. p. ; 24 cm. STI/PUB/1344 ISBN 978–92–0–107008–1 Includes bibliographical references. 1. Radiopharmaceuticals — Quality control. 2. Tomography, Emission — Quality control. I. International Atomic Energy Agency. IAEAL 09–00567 FOREWORD Positron emission tomography (PET) methodologies, which visualize in vivo biochemical, physiological and pharmacological processes, together with the availability of hybrid imaging modalities (PET with computer tomography (PET/CT) imaging), have revolutionized patient diagnosis, disease staging, disease management and therapy follow-up. These technologies have opened up fascinating possibilities for new non-invasive medical care and individualized patient management unlike those seen before in a clinical setting. There is immense global interest in PET, with accelerated investment in the clinical setting. The radiotracers used for PET are very different from conventional nuclear medicine radiopharmaceuticals. They have extremely short half-lives, which means that they have to be produced close to the clinical user. The time available for the labelling of PET molecules (including purification and quality control) is very limited, which presents new challenges and a need for more proficient systems to be established before clinical use. The busy and demanding nature of clinical settings adds to the complexities and creates a need for more robust quality management programmes. This publication focuses on clinical settings and was compiled following several IAEA Consultants Meetings and with the benefit of the contributions of individual experts. It aims to raise awareness of the issues involved and suggests ways of reducing risk. The purpose of these guidelines is to encourage a proactive approach to each aspect of parametric release and to propose practical test methods for each criterion for parametric acceptance, thereby helping end users to ensure the quality of PET products. It is hoped that these criteria will stimulate further cooperation among various countries worldwide in the development of a set of harmonized acceptance test criteria for PET systems and sensible quality assurance (QA) standards for all PET tracers. Many countries and IAEA Member States are in the process of creating rules governing the production of clinically safe and effective PET radiopharmaceuticals for human use. Where such rules are available, it is encouraged that they be used. The guidelines presented in this book will be useful for those Member States who have yet to develop such rules or who simply wish to adopt them for national usage. They are not meant to replace existing regulatory or local oversight. This publication should be a useful resource for both researchers and practitioners. Continuous reliable development and quality supply of radiopharmaceuticals for patients worldwide is vital for sustained development of nuclear medicine. The IAEA is grateful to all the contributors and reviewers of these guidelines. The IAEA officer responsible for this publication was K.K. Solanki of the Division of Human Health. EDITORIAL NOTE Although great care has been taken to maintain the accuracy of information contained in this publication, neither the IAEA nor its Member States assume any responsibility for consequences which may arise from its use. The use of particular designations of countries or territories does not imply any judgement by the publisher, the IAEA, as to the legal status of such countries or territories, of their authorities and institutions or of the delimitation of their boundaries. The mention of names of specific companies or products (whether or not indicated as registered) does not imply any intention to infringe proprietary rights, nor should it be construed as an endorsement or recommendation on the part of the IAEA. CONTENTS 1. INTRODUCTION . 1 1.1. Scope . 1 1.2. Background . 1 1.3. PET radiopharmaceuticals . 2 1.4. Differences between 99mTc and PET radiopharmacy . 5 1.5. IAEA operational guidance on hospital radiopharmacy . 8 1.6. Overview of quality programme . 11 1.7. Criteria for synthesis of a new PET radiopharmaceutical . 13 1.8. Summary of a new class of PET tracers . 15 1.9. IAEA consultants meeting . 19 1.10. The role of this publication . 20 2. EFFECTIVE TRANSLATION OF PET RESEARCH INTO CLINICAL PRACTICE . 21 2.1. Scope . 21 2.2. Chemical aspects . 22 2.3. Biological aspects . 24 2.4. First studies on humans . 26 2.5. Conclusions . 27 3. OVERSIGHT COMMITTEES . 27 3.1. Scope . 27 3.2. Introduction . 28 3.3. Role of oversight committees . 29 3.4. Overview of existing regulations . 29 3.5. Alternative to existing oversight committees . 38 3.6. EANM guidelines for PET radiopharmacy . 43 4. TERMINOLOGY . 44 4.1. Radiopharmaceuticals . 44 4.2. Charged particle bombardment of target materials . 45 4.3. Radioactive decay . 46
Load more

Recommended publications
  • A Comparison of Imaging Modalities for the Diagnosis of Osteomyelitis
    A comparison of imaging modalities for the diagnosis of osteomyelitis Brandon J. Smith1, Grant S. Buchanan2, Franklin D. Shuler2 Author Affiliations: 1. Joan C Edwards School of Medicine, Marshall University, Huntington, West Virginia 2. Marshall University The authors have no financial disclosures to declare and no conflicts of interest to report. Corresponding Author: Brandon J. Smith Marshall University Joan C. Edwards School of Medicine Huntington, West Virginia Email: [email protected] Abstract Osteomyelitis is an increasingly common pathology that often poses a diagnostic challenge to clinicians. Accurate and timely diagnosis is critical to preventing complications that can result in the loss of life or limb. In addition to history, physical exam, and laboratory studies, diagnostic imaging plays an essential role in the diagnostic process. This narrative review article discusses various imaging modalities employed to diagnose osteomyelitis: plain films, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, bone scintigraphy, and positron emission tomography (PET). Articles were obtained from PubMed and screened for relevance to the topic of diagnostic imaging for osteomyelitis. The authors conclude that plain films are an appropriate first step, as they may reveal osteolytic changes and can help rule out alternative pathology. MRI is often the most appropriate second study, as it is highly sensitive and can detect bone marrow changes within days of an infection. Other studies such as CT, ultrasound, and bone scintigraphy may be useful in patients who cannot undergo MRI. CT is useful for identifying necrotic bone in chronic infections. Ultrasound may be useful in children or those with sickle-cell disease. Bone scintigraphy is particularly useful for vertebral osteomyelitis.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Isotope Production Potential at Sandia National Laboratories: Product, Waste, Packaging, and Transportation*
    Isotope Production Potential at Sandia National Laboratories: Product, Waste, Packaging, and Transportation* A. J. Trennel Transportation Systems Department *- *-, o / /"-~~> Sandia National Laboratories** ' J Albuquerque, NM 87185 O Q T » Abstract The U.S. Congress directed the U.S. Department of Energy to establish a domestic source of molybdenum-99, an essential isotope used in nuclear medicine and radiopharmacology. An Environmental Impact Statement for production of 99Mo at one of four candidate sites is being prepared. As one of the candidate sites, Sandia National Laboratories is developing the Isotope Production Project. Using federally approved processes and procedures now owned by the U.S. Department of Energy, and existing facilities that would be modified to meet the production requirements, the Sandia National Laboratories' Isotope Project would manufacture up to 30 percent of the U.S. market, with the capacity to meet 100 percent of the domestic need if necessary. This paper provides a brief overview of the facility, equipment, and processes required to produce isotopes. Packaging and transportation issues affecting both product and waste are addressed, and the storage and disposal of the four low-level radioactive waste types generated by the production program are considered. Recommendations for future development are provided. This work was performed at Sandia National Laboratories, Albuquerque, New Mexico, for the U.S. Department of Energy under Contract DE-AC04-94AL85000. A U.S. Department of Energy facility. DISTRPJTO OF THIS DOCUMENT IS UNLIMITED #t/f W A8 1 fcll PROJECT NEED AND BACKGROUND Nuclear medicine is an expanding segment of today's medical and pharmaceutical communities. Specific radioactive isotopes are vital, with molybdenum-99 (99Mo) being the most important medical isotope.
    [Show full text]
  • Consensus Nomenclature Rules for Radiopharmaceutical Chemistry – Setting the Record Straight
    ÔØ ÅÒÙ×Ö ÔØ Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight Heinz H. Coenen, Antony D. Gee, Michael Adam, Gunnar Antoni, Cathy S. Cutler, Yasuhisa Fujibayashi, Jae Min Jeong, Robert H. Mach, Thomas L. Mindt, Victor W. Pike, Albert D. Windhorst PII: S0969-8051(17)30318-9 DOI: doi: 10.1016/j.nucmedbio.2017.09.004 Reference: NMB 7967 To appear in: Nuclear Medicine and Biology Received date: 21 September 2017 Accepted date: 22 September 2017 Please cite this article as: Coenen Heinz H., Gee Antony D., Adam Michael, Antoni Gunnar, Cutler Cathy S., Fujibayashi Yasuhisa, Jeong Jae Min, Mach Robert H., Mindt Thomas L., Pike Victor W., Windhorst Albert D., Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight, Nuclear Medicine and Biology (2017), doi: 10.1016/j.nucmedbio.2017.09.004 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Consensus nomenclature rules for radiopharmaceutical chemistry – setting the record straight Recommended guidelines, assembled by an international and inter- society working group after extensive consultation with peers in the wider field of nuclear chemistry and radiopharmaceutical sciences. Heinz H. Coenen1*, Antony D. Gee2*, Michael Adam3, Gunnar Antoni4, Cathy S.
    [Show full text]
  • Time-Of-Flight PET Map out Goals by Joel S
    Volume 3, Issue 4 FALL 2006 pet center of excellence newsletter PET COE Board Meets with Industry Advisory Group to Time-of-Flight PET Map Out Goals By Joel S. Karp, PhD he idea to use time-of-flight (TOF) information in PET image reconstruction By James W. Fletcher, MD Twas originally proposed in the 1960s at a very early stage in the development of President, PET Center of Excellence positron imaging. By the early 1980s, fully functional TOF PET systems had been built, An inaugural meet- not long after the first conventional PET systems were completed. Why then did it take ing was held recently so long to introduce a clinical TOF PET scanner, and how does it compare to the first in Chicago between the TOF PET instruments built 25 years ago? PET Center of Excel- Time-of-Flight Theory lence Board of Directors The concept of time-of-flight means simply that for each annihilation event, we note (BOD) and the Industry the precise time that each of the coincident photons is detected and calculate the dif- Advisory Group (IAG). ference. Since the closer photon will arrive at its detector first, the difference in arrival The meeting was very times helps pin down the location of the annihilation event along the line between the James W. Fletcher well attended with rep- two detectors. resentation from a large To understand why this information is useful, we need to recall that normally in cross-section of industry. PET we collect line pair data at many angles and create tomographic images through The interaction and discussion at the con- traditional filtered back-projection or through an iterative series of back- and forward- joint morning meeting was lively and infor- projection steps.
    [Show full text]
  • Clinical Anesthesia and Analgesia in Fish
    WellBeing International WBI Studies Repository 1-2012 Clinical Anesthesia and Analgesia in Fish Lynne U. Sneddon University of Liverpool Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/acwp_vsm Part of the Animal Studies Commons, Other Animal Sciences Commons, and the Veterinary Toxicology and Pharmacology Commons Recommended Citation Sneddon, L. U. (2012). Clinical anesthesia and analgesia in fish. Journal of Exotic Pet Medicine, 21(1), 32-43. This material is brought to you for free and open access by WellBeing International. It has been accepted for inclusion by an authorized administrator of the WBI Studies Repository. For more information, please contact [email protected]. Clinical Anesthesia and Analgesia in Fish Lynne U. Sneddon University of Liverpool KEYWORDS Analgesics, anesthetic drugs, fish, local anesthetics, opioids, NSAIDs ABSTRACT Fish have become a popular experimental model and companion animal, and are also farmed and caught for food. Thus, surgical and invasive procedures in this animal group are common, and this review will focus on the anesthesia and analgesia of fish. A variety of anesthetic agents are commonly applied to fish via immersion. Correct dosing can result in effective anesthesia for acute procedures as well as loss of consciousness for surgical interventions. Dose and anesthetic agent vary between species of fish and are further confounded by a variety of physiological parameters (e.g., body weight, physiological stress) as well as environmental conditions (e.g., water temperature). Combination anesthesia, where 2 anesthetic agents are used, has been effective for fish but is not routinely used because of a lack of experimental validation. Analgesia is a relatively underexplored issue in regards to fish medicine.
    [Show full text]
  • Progress in Radiopharmacology
    INIS-mf—11544 Proceedings of the Vth International Symposium on Radiopharmacology PROGRESS IN RADIOPHARMACOLOGY EDITORS A. E. A. MITTA R. A. CARO C. O. CANELLAS 986 BUENOS AIRES - REPUBLICA ARGENTINA 1987 & ,f<? 000 Y'{ Proceedings of the Vth International Symposium on Radiopharmacology PROGRESS IN RADIOPHARMACOLOGY EDITORS A. E. A. MITTA R. A. CARO C. O. CANELLAS 986 BUENOS AIRES - REPUBLICA ARGENTINA 1987 Proceedings of the Vth International Symposium on Radiopharmacology PROGRESS IN RADIOPHARMACOLOGY EDITORS A. E. A. MITTA Comision Nacional de Energia Atomica Buenos Aires, Republics Argentina R. A. CARO Facultad de Farmacia y Bioquimica Universidad de Buenos Aires, Republics Argentina C. O. CAIVIELLAS Comision Nacional de Energia Atomica Buenos Aires, Republica Argentina PREFACE This book contains most of the papers presented at the V International Symposium on Radiopharmacology held at Buenos Aires, Argentina, from the 29th to the 31st October, 1986. The papers were put into the same order as they were presented at the symposium. The V Simposium was sponsored by the Argentine Atomic Energy Commission, which allowed, among other things, the edition of this book. I want to acknowledge specially the cordial assistance of Profs.DlSiRicardo.A.Caro and Carlos. O.Canellas in the publication of the present book. PREFACE The Executive Committee of the V International Symposium on Radiopharmacology acknowledges deeply the participation of all those who presented their paper, discussed the results or simply assisted to the sympos ium. The proceedings we are publishing herewith are the result of the efforts of the authors who sent us the full papers, as well as the excellent work done by the Printing Department of the Argentine Atomic Energy Commission.
    [Show full text]
  • Advertising (PDF)
    CintiChemAreTheTechnetìumHeaviestYou'll99mGeneratorsFind- OnPurpose YourSafety isOurConcernjitt Technetium 99m Generators from And all ClntiChem Technetium 99m Cintichem, Inc. have 3.77 inches of lead Generators from Medi-Physics surrounding the column for maximum incorporate the following important radiation protection. The secondary advantages: shield adds 5/8" more lead to make our •A NEW STERILE NEEDLE is utilized for generators safer yet. And only MPI Gen each elution, reducing the chances of a erators offer depleted uranium shielding septic or pyrogenic situation occurring in higher calibrations, designed to max in routine clinical usage. imize radiation protection, convenience •See, 10cc AND 20cc EVACUATED and reduce costs. With 20 sizes and 2 ELUTION VIALS are available, allowing calibration days, we can meet virtually you to optimize the elution concentra every need. tion to meet your needs. Convenience is also designed INTO every •RIGID QUALITY CONTROL TESTING, MPI Generator. It is the only generator which includes an elution check on with rapid, easy horizontal elution via a each Generator, assures that it meets shielded elution port. The simple, one- our rigid internal specifications. The step elution reduces work time while assurance that 20 years experience in eliminating direct eye exposure during nuclear medicine brings. the elution process. Eluate sterility is •ACCESSIBLE CUSTOMER SERVICE assured by the 0.22 micron filter on the on toll free telephone numbers. Our terminal fluid line and an autoclaved service personnel have in depth back column. grounds in research, development, technical and clinical applications in nuclear medicine. We are concerned about your safety. That will be evident when you receive your first CintiChem generator from MPI.
    [Show full text]
  • Basics and Principles of Radiopharmaceuticals for PET/CT
    European Journal of Radiology 73 (2010) 461–469 Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Review Basics and principles of radiopharmaceuticals for PET/CT W. Wadsak a, M. Mitterhauser a,b,∗ a Department of Nuclear Medicine, Medical University of Vienna, Austria b Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Austria article info abstract Article history: The presented review provides general background on PET radiopharmaceuticals for oncological appli- Received 1 December 2009 cations. Special emphasis is put on radiopharmacological, radiochemical and regulatory aspects. This Accepted 15 December 2009 review is not meant to give details on all different PET tracers in depth but to provide insights into the general principles coming along with their preparation and use. Keywords: The PET tracer plays a pivotal role because it provides the basis both for image quality and clinical Radiopharmaceutical interpretation. It is composed of the radionuclide (signaller) and the molecular vehicle which determines Tracer the (bio-)chemical properties (e.g. binding characteristics, metabolism, elimination rate). Radiopharmacology Radiochemistry © 2010 Published by Elsevier Ireland Ltd. This section is intended to provide general background on PET resulting in abnormal function it can probably be visualized long radiopharmaceuticals for oncological application. Special empha- before morphological manifestation. sis is put on radiopharmacological, radiochemical and regulatory Basically, there are three major disciplines that have to inter- aspects. This review is not meant to give details on all different PET act and collaborate closely to enable the successful application of tracers in depth but to provide insights into the general principles PET/CT in a clinical setting: medical physics, radiopharmaceuti- coming along with their preparation and use.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • The Effectiveness of Ketamine As an Anesthetic for Fish (Rainbow Trout – Oncorhynchus Mykiss)
    Research Article Oceanogr Fish Open Access J Volume 13 Issue 1 - January 2021 Copyright © All rights are reserved by Mohammedsaeed Ganjoor DOI: 10.19080/OFOAJ.2021.13.555852 The Effectiveness of Ketamine as an Anesthetic for Fish (Rainbow Trout – Oncorhynchus mykiss) Mohammedsaeed Ganjoor*, Maysam Salahi-ardekani, Sajad Nazari, Javad Mahdavi, Esmail Kazemi and Mohsen Mohammadpour Genetic and Breeding Research Centre for Cold Water Fishes (ShahidMotahary Cold-water Fishes Center), Iranian Fisheries Science Research Institute, Iran Submission: November 03, 2020; Published: January 12, 2021 Corresponding author: Mohammedsaeed Ganjoor, Genetic and Breeding Research Centre for Cold Water Fishes (ShahidMotahary Cold-water Fishes Center), Iranian Fisheries Science Research Institute, Agricultural Research Education and Extension Organization (AREEO), Yasuj, IRAN Email: [email protected] & [email protected] Abstract Ketamine was evaluated as water-soluble anesthetics drug for a species of fish, rainbow trout (Oncorhynchus mykiss). Fish (size ~20 - ~240 anesthesiagr.) were exposed duration to (stage1 a 100-ppm to 3) concentrationand recovery duration of Ketamine was recorded.solution (dissolved Also, surveillance in water), was they evaluated were arranged after recovery. in 4 treatments Ketamine wasbased effective on their to weight range (Treatment-1= 22.8±3.4 g; Treatment-2= 51.7±4.4 g; Treatment-3= 69.8±5.2 g and Treatment-4= 243.8±20.7 g). Elapsed time for cause anesthesia in the fish as 100 ppm concentration. 10 fishes of each treatment (%100) were anesthetized and were induced in stageIII-Plane3 of anesthesia within 2-3 min after exposure to anesthetic solution (Treatment-1= 110.3±3.5 seconds; Treatment-2= 140.0±5.9 sec; Treatment-3= 180.0±5.8 sec and Treatment-4= 190.0±5.8 sec).
    [Show full text]
  • Recent Advances in Intravenous Anesthesia and Anesthetics
    Recent advances in intravenous anesthesia and anesthetics The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mahmoud, Mohamed, and Keira P. Mason. 2018. “Recent advances in intravenous anesthesia and anesthetics.” F1000Research 7 (1): F1000 Faculty Rev-470. doi:10.12688/f1000research.13357.1. http:// dx.doi.org/10.12688/f1000research.13357.1. Published Version doi:10.12688/f1000research.13357.1 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160088 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA F1000Research 2018, 7(F1000 Faculty Rev):470 Last updated: 17 APR 2018 REVIEW Recent advances in intravenous anesthesia and anesthetics [version 1; referees: 2 approved] Mohamed Mahmoud1, Keira P. Mason 2 1Department of Anesthesiology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA 2Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children’s Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA, 02115, USA First published: 17 Apr 2018, 7(F1000 Faculty Rev):470 (doi: Open Peer Review v1 10.12688/f1000research.13357.1) Latest published: 17 Apr 2018, 7(F1000 Faculty Rev):470 (doi: 10.12688/f1000research.13357.1) Referee Status: Abstract Invited Referees Anesthesiology, as a field, has made promising advances in the discovery of 1 2 novel, safe, effective, and efficient methods to deliver care.
    [Show full text]